These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38372353)

  • 41. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
    Qin Y; Xu G
    Front Immunol; 2022; 13():1053120. PubMed ID: 36569859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
    Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
    J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomaterials for chimeric antigen receptor T cell engineering.
    Niu H; Zhao P; Sun W
    Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
    Morgan MA; Schambach A
    Front Immunol; 2018; 9():2493. PubMed ID: 30420856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
    Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
    Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
    MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
    Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
    Mao R; Hussein MS; He Y
    Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
    Bunse M; Höpken UE
    Methods Mol Biol; 2022; 2521():67-83. PubMed ID: 35732993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.